Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Charles A. Baker sold 2,000 shares of the stock in a transaction that occurred on Friday, September 29th. The shares were sold at an average price of $450.00, for a total transaction of $900,000.00. Following the completion of the transaction, the director now directly owns 11,000 shares of the company’s stock, valued at $4,950,000. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Shares of Regeneron Pharmaceuticals, Inc. (REGN) traded down 1.43% during trading on Tuesday, hitting $455.63. The company’s stock had a trading volume of 595,334 shares. Regeneron Pharmaceuticals, Inc. has a one year low of $325.35 and a one year high of $543.55. The stock has a market cap of $48.31 billion, a PE ratio of 45.71 and a beta of 1.63. The company has a 50-day moving average price of $461.31 and a 200-day moving average price of $450.61.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.67 by $1.50. The firm had revenue of $1.47 billion during the quarter, compared to the consensus estimate of $1.36 billion. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The firm’s revenue for the quarter was up 21.2% on a year-over-year basis. During the same period last year, the firm posted $2.82 EPS. Equities analysts predict that Regeneron Pharmaceuticals, Inc. will post $14.93 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Insider Selling: Regeneron Pharmaceuticals, Inc. (REGN) Director Sells 2,000 Shares of Stock” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. & international copyright law. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/10/03/insider-selling-regeneron-pharmaceuticals-inc-regn-director-sells-2000-shares-of-stock.html.

Several hedge funds have recently added to or reduced their stakes in REGN. Intl Fcstone Inc. purchased a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $346,000. Lord Abbett & CO. LLC acquired a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $51,931,000. Toronto Dominion Bank raised its position in shares of Regeneron Pharmaceuticals by 25.8% during the 2nd quarter. Toronto Dominion Bank now owns 25,835 shares of the biopharmaceutical company’s stock worth $12,686,000 after purchasing an additional 5,295 shares during the last quarter. WINTON GROUP Ltd acquired a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $713,000. Finally, Public Employees Retirement System of Ohio raised its position in shares of Regeneron Pharmaceuticals by 1.6% during the 2nd quarter. Public Employees Retirement System of Ohio now owns 54,288 shares of the biopharmaceutical company’s stock worth $26,663,000 after purchasing an additional 867 shares during the last quarter. Institutional investors and hedge funds own 67.95% of the company’s stock.

REGN has been the subject of several research reports. Leerink Swann reiterated an “outperform” rating and set a $573.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Thursday, June 22nd. Raymond James Financial, Inc. reissued an “outperform” rating and set a $547.00 price objective (up from $475.00) on shares of Regeneron Pharmaceuticals in a report on Thursday, June 22nd. Bank of America Corporation reissued a “buy” rating and issued a $593.00 target price (up from $589.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, July 21st. BMO Capital Markets reissued a “market perform” rating and issued a $484.00 target price (up from $421.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, July 21st. Finally, Sanford C. Bernstein lowered Regeneron Pharmaceuticals from an “outperform” rating to a “market perform” rating and raised their target price for the stock from $410.00 to $480.00 in a research note on Monday, June 26th. They noted that the move was a valuation call. Two research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $487.26.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Insider Buying and Selling by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Stock Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.